You are here: Home: BCU CME | 2005: Editor's office
 
     
 

EDITOR
Neil Love, MD

ASSOCIATE EDITORS
Michelle Paley, MD
Richard Kaderman, PhD
Kathryn Ault Ziel, PhD

WRITERS
Lilliam Sklaver Poltorack
PharmD
Sally Bogert, RNC, WHCNP
Douglas Paley

CME DIRECTOR
 Michelle Paley, MD

CONTENT VALIDATION
 Margaret Peng

DIRECTOR, CREATIVE
AND COPY EDITING
Aura Herrmann

CREATIVE MANAGER
Fernando Rendina

DESIGN QUALITY
CONTROL DIRECTOR
Ben Belin

ASSOCIATE DESIGNER
Maria Agudelo-Schaefer

GRAPHIC DESIGNER
Jason Cunnius

JUNIOR DESIGNER
Shantia Daniel

SENIOR PRODUCTION EDITOR
Alexis Oneca

TRAFFIC COORDINATOR
Tere Sosa

COPY EDITORS
Joy Davis
Mary DiNunzio
Rosemary Hulce
Pat Morrissey/Havlin
Susan Petrone
Carol Peschke

PRODUCTION MANAGER
Patricia Kappes

AUDIO PRODUCTION
Frank Cesarano

TECHNICAL SERVICES
Arly Ledezma

WEB MASTER
John Ribeiro

EDITORIAL ASSISTANTS
Catherine Marshall
Patricia McWhorter
Christina Rodriguez
Ginelle Suarez

CONTACT INFORMATION:
Neil Love, MD

RESEARCH TO PRACTICE
One Biscayne Tower
2 South Biscayne Boulevard
Suite 3600
Miami, FL 33131
Fax: (305) 377-9998
Email: NLove@ResearchToPractice.net

FOR CME INFORMATION:
Email: CME@ResearchToPractice.net

This program was supported by education grants from AstraZeneca Pharmaceuticals LP and Roche Laboratories Inc.

The audio tapes, compact discs, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

 
 
 
     
 
 


 
Editor’s Note:
Common questions about breast cancer from oncologists in community practice


Case 1: An active 79-year-old woman with a 7.5-centimeter, Grade II, ER/PR-positive, HER2-negative breast cancer with lymphovascular invasion and three positive nodes (from the practice of Dr Martha A Tracy)
- Select publications

Case 2: A 41-year-old premenopausal woman with an ER/PR-positive, HER2-positive infiltrating ductal carcinoma and six positive lymph nodes (from the practice of Dr Herbert I Rappaport)
- Select publications

Case 3: A 68-year-old woman with disease progression 10 years after presenting with hormone receptor-positive diffuse metastatic disease to the bone (from the practice of Dr Ghaleb A Saab)
- Select publications

Case 4: A 91-year-old woman with dementia who was diagnosed with Stage II, ER-positive, lymph node-negative breast cancer 15 years ago and now has diffuse bone metastases (from the practice of Dr Juliann M Smith)
- Select publications

Case 5: A 41-year-old surgically postmenopausal woman with a 3.5-centimeter, ER/PR-positive, HER2-positive tumor and two positive lymph nodes (from the practice of Dr Herbert I Rappaport)
- Select publications

Case 6: A 45-year-old premenopausal woman with a 0.7-cm, ER/PR-positive, HER2-positive tumor with 25 percent high-grade DCIS and an Oncotype DX™ recurrence score of 16 (from the practice of Dr Steven W Papish)
- Select publications

Case 7: A woman who presented in 1989 with an infiltrating lobular carcinoma and 21 positive nodes and was treated with adjuvant chemotherapy and tamoxifen and then develops metastatic disease and is treated over the next 11 years with a variety of chemotherapeutic and hormonal agents (from the practice of Dr Pamela Drullinsky)
- Select publications

Case 8: A 35-year-old woman with a 3.5-cm, ER/PR-positive, HER2-positive infiltrating ductal carcinoma and two positive sentinel lymph nodes treated on the nontrastuzumab- containing arm of the Intergroup N9831 trial (from the practice of Dr Pamela Drullinsky)
- Select publications
 
CME Information
Faculty Disclosures
Editor's Office